Cannabinoids, a group of C21 compounds present in Cannabis sativa L., their carboxylic acids, analogs, and transformation products, are the active ingredients found in hasish and marihuana. (-)-trans-D9-tetrahydrocannabinol (D9-THC) is the major psychopharmacologically active component of cannabis. Cannabis affect cognition and memory, euphoria and sedation, and antinociception (analgesia) without the respiratory depression problems associated with opioid analgesics. D9-THC is also immunosuppressive and impairs cell-mediated immunity, humoral immunity and cellular defenses against a variety of infectious agents both in vivo and in vitro. To date, two sub-types of the G-protein coupled cannabinoid receptor, CB1 and CB2, have been identified. The first brain-derived endogenous cannabinoids, an unsaturated fatty-acid ethanolamide, arachidonylethanolamide (AEA, also called anandamide) was found in brain. AEA has higher affinity for the CB1 than for the CB2. An 18 amino acid peptide sequence near the cytoplasmic, C-terminus of rat CB2 Cannabinoid Receptor 2. Peptide sequence is 88% conserved in mouse, and 82% in human CB2. No significant sequence homology exists with CB1. Control Peptide for C1075-75 and C1075-75F Application(s): ELISA: 1:10,000-1:100,000 using 50-100 ng of control peptide/well Storage and Stability: Lyophilized powder is stable for at least 12 months at -20C Reconstituted product must be stored in aliquots at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Purity:
Purified
Form:
Supplied as a lyophilized powder from PBS, 0.05% sodium azide.
* VAT and and shipping costs not included. Errors and price changes excepted
